CN1352935A - 含有氨基苯酚衍生物和异黄酮类物质的化妆品组合物 - Google Patents
含有氨基苯酚衍生物和异黄酮类物质的化妆品组合物 Download PDFInfo
- Publication number
- CN1352935A CN1352935A CN01138426A CN01138426A CN1352935A CN 1352935 A CN1352935 A CN 1352935A CN 01138426 A CN01138426 A CN 01138426A CN 01138426 A CN01138426 A CN 01138426A CN 1352935 A CN1352935 A CN 1352935A
- Authority
- CN
- China
- Prior art keywords
- compositions
- isoflavone
- substance
- group
- phenol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 57
- CDAWCLOXVUBKRW-UHFFFAOYSA-N 2-aminophenol Chemical class NC1=CC=CC=C1O CDAWCLOXVUBKRW-UHFFFAOYSA-N 0.000 title claims abstract description 19
- CJWQYWQDLBZGPD-UHFFFAOYSA-N isoflavone Natural products C1=C(OC)C(OC)=CC(OC)=C1C1=COC2=C(C=CC(C)(C)O3)C3=C(OC)C=C2C1=O CJWQYWQDLBZGPD-UHFFFAOYSA-N 0.000 title claims description 24
- 235000008696 isoflavones Nutrition 0.000 title claims description 24
- GOMNOOKGLZYEJT-UHFFFAOYSA-N isoflavone Chemical compound C=1OC2=CC=CC=C2C(=O)C=1C1=CC=CC=C1 GOMNOOKGLZYEJT-UHFFFAOYSA-N 0.000 title claims description 23
- 239000000126 substance Substances 0.000 title claims description 17
- 239000002537 cosmetic Substances 0.000 title claims description 9
- 230000035614 depigmentation Effects 0.000 claims abstract description 15
- 238000004061 bleaching Methods 0.000 claims abstract description 14
- 238000002360 preparation method Methods 0.000 claims abstract description 9
- -1 Daidezin Chemical compound 0.000 claims description 30
- 150000001875 compounds Chemical class 0.000 claims description 17
- 230000000855 fungicidal effect Effects 0.000 claims description 16
- 239000003795 chemical substances by application Substances 0.000 claims description 12
- BECNKUVYBNETOM-UHFFFAOYSA-N ethyl n-(4-hydroxyphenyl)carbamate Chemical group CCOC(=O)NC1=CC=C(O)C=C1 BECNKUVYBNETOM-UHFFFAOYSA-N 0.000 claims description 11
- DCTLJGWMHPGCOS-UHFFFAOYSA-N Osajin Chemical compound C1=2C=CC(C)(C)OC=2C(CC=C(C)C)=C(O)C(C2=O)=C1OC=C2C1=CC=C(O)C=C1 DCTLJGWMHPGCOS-UHFFFAOYSA-N 0.000 claims description 10
- OUZCFMSJGDEXRT-UHFFFAOYSA-N Scandinone Natural products O=C1C=2C(OC)=C(CC=C(C)C)C=3OC(C)(C)C=CC=3C=2OC=C1C1=CC=C(O)C=C1 OUZCFMSJGDEXRT-UHFFFAOYSA-N 0.000 claims description 10
- 238000012216 screening Methods 0.000 claims description 10
- ZQSIJRDFPHDXIC-UHFFFAOYSA-N Daidzein Natural products C1=CC(O)=CC=C1C1=COC2=CC(O)=CC=C2C1=O ZQSIJRDFPHDXIC-UHFFFAOYSA-N 0.000 claims description 9
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 8
- KQMVAGISDHMXJJ-UHFFFAOYSA-N prunetin Chemical compound C=1C(OC)=CC(O)=C(C2=O)C=1OC=C2C1=CC=C(O)C=C1 KQMVAGISDHMXJJ-UHFFFAOYSA-N 0.000 claims description 8
- 229920006395 saturated elastomer Polymers 0.000 claims description 8
- 238000000034 method Methods 0.000 claims description 7
- ZCOLJUOHXJRHDI-CMWLGVBASA-N genistein 7-O-beta-D-glucoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=C2C(=O)C(C=3C=CC(O)=CC=3)=COC2=C1 ZCOLJUOHXJRHDI-CMWLGVBASA-N 0.000 claims description 6
- WITLAWYGGVAFLU-UHFFFAOYSA-N 3-(6-methoxy-1,3-benzodioxol-5-yl)-8,8-dimethylpyrano[2,3-f]chromen-4-one Chemical compound C1=CC(C)(C)OC2=CC=C(C(C(C3=CC=4OCOC=4C=C3OC)=CO3)=O)C3=C21 WITLAWYGGVAFLU-UHFFFAOYSA-N 0.000 claims description 4
- BHIIMRBCELSOFD-UHFFFAOYSA-N 7-hydroxy-3-(6-methoxy-1,3-benzodioxol-5-yl)chromen-4-one Chemical compound OC1=CC=C2C(=O)C(C3=CC=4OCOC=4C=C3OC)=COC2=C1 BHIIMRBCELSOFD-UHFFFAOYSA-N 0.000 claims description 4
- ALFNTRJPGFNJQV-UHFFFAOYSA-N Cajanin Chemical compound C=1C(OC)=CC(O)=C(C2=O)C=1OC=C2C1=CC=C(O)C=C1O ALFNTRJPGFNJQV-UHFFFAOYSA-N 0.000 claims description 4
- VOOFPOMXNLNEOF-UHFFFAOYSA-N Irisolidone Chemical compound C1=CC(OC)=CC=C1C1=COC2=CC(O)=C(OC)C(O)=C2C1=O VOOFPOMXNLNEOF-UHFFFAOYSA-N 0.000 claims description 4
- OEYQBKYISMRWQB-UHFFFAOYSA-N Santal Chemical compound C=1C(OC)=CC(O)=C(C2=O)C=1OC=C2C1=CC=C(O)C(O)=C1 OEYQBKYISMRWQB-UHFFFAOYSA-N 0.000 claims description 4
- KJGPBYUQZLUKLL-UHFFFAOYSA-N afrormosin Chemical compound C1=CC(OC)=CC=C1C1=COC2=CC(O)=C(OC)C=C2C1=O KJGPBYUQZLUKLL-UHFFFAOYSA-N 0.000 claims description 4
- HKQYGTCOTHHOMP-UHFFFAOYSA-N formononetin Chemical compound C1=CC(OC)=CC=C1C1=COC2=CC(O)=CC=C2C1=O HKQYGTCOTHHOMP-UHFFFAOYSA-N 0.000 claims description 4
- IOYHCQBYQJQBSK-UHFFFAOYSA-N orobol Chemical compound C=1C(O)=CC(O)=C(C2=O)C=1OC=C2C1=CC=C(O)C(O)=C1 IOYHCQBYQJQBSK-UHFFFAOYSA-N 0.000 claims description 4
- FPIOBTBNRZPWJW-UHFFFAOYSA-N pratensein Chemical compound C1=C(O)C(OC)=CC=C1C1=COC2=CC(O)=CC(O)=C2C1=O FPIOBTBNRZPWJW-UHFFFAOYSA-N 0.000 claims description 4
- OBBCRPUNCUPUOS-UHFFFAOYSA-N tectorigenin Chemical compound O=C1C2=C(O)C(OC)=C(O)C=C2OC=C1C1=CC=C(O)C=C1 OBBCRPUNCUPUOS-UHFFFAOYSA-N 0.000 claims description 4
- GMTUGPYJRUMVTC-UHFFFAOYSA-N Daidzin Natural products OC(COc1ccc2C(=O)C(=COc2c1)c3ccc(O)cc3)C(O)C(O)C(O)C=O GMTUGPYJRUMVTC-UHFFFAOYSA-N 0.000 claims description 3
- KYQZWONCHDNPDP-UHFFFAOYSA-N Daidzoside Natural products OC1C(O)C(O)C(CO)OC1OC1=CC=C2C(=O)C(C=3C=CC(O)=CC=3)=COC2=C1 KYQZWONCHDNPDP-UHFFFAOYSA-N 0.000 claims description 3
- ZCOLJUOHXJRHDI-FZHKGVQDSA-N Genistein 7-O-glucoside Natural products O([C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O1)c1cc(O)c2C(=O)C(c3ccc(O)cc3)=COc2c1 ZCOLJUOHXJRHDI-FZHKGVQDSA-N 0.000 claims description 3
- CJPNHKPXZYYCME-UHFFFAOYSA-N Genistin Natural products OCC1OC(Oc2ccc(O)c3OC(=CC(=O)c23)c4ccc(O)cc4)C(O)C(O)C1O CJPNHKPXZYYCME-UHFFFAOYSA-N 0.000 claims description 3
- YCUNGEJJOMKCGZ-UHFFFAOYSA-N Pallidiflorin Natural products C1=CC(OC)=CC=C1C1=COC2=CC=CC(O)=C2C1=O YCUNGEJJOMKCGZ-UHFFFAOYSA-N 0.000 claims description 3
- 235000007240 daidzein Nutrition 0.000 claims description 3
- KYQZWONCHDNPDP-QNDFHXLGSA-N daidzein 7-O-beta-D-glucoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC=C2C(=O)C(C=3C=CC(O)=CC=3)=COC2=C1 KYQZWONCHDNPDP-QNDFHXLGSA-N 0.000 claims description 3
- TZBJGXHYKVUXJN-UHFFFAOYSA-N genistein Natural products C1=CC(O)=CC=C1C1=COC2=CC(O)=CC(O)=C2C1=O TZBJGXHYKVUXJN-UHFFFAOYSA-N 0.000 claims description 3
- 235000006539 genistein Nutrition 0.000 claims description 3
- 229940045109 genistein Drugs 0.000 claims description 3
- SLPPBRLLAWJEIM-UHFFFAOYSA-N 1-ethyl-3-(4-hydroxyphenyl)urea Chemical compound CCNC(=O)NC1=CC=C(O)C=C1 SLPPBRLLAWJEIM-UHFFFAOYSA-N 0.000 claims description 2
- HHGPYJLEJGNWJA-UHFFFAOYSA-N 5-hydroxy-3,3',4',7-tetramethoxyflavone Chemical compound C=1C(OC)=CC(O)=C(C(C=2OC)=O)C=1OC=2C1=CC=C(OC)C(OC)=C1 HHGPYJLEJGNWJA-UHFFFAOYSA-N 0.000 claims description 2
- 229940124091 Keratolytic Drugs 0.000 claims description 2
- DLXIJJURUIXRFK-UHFFFAOYSA-N Retusin(Dalbergia) Natural products C1=CC(OC)=CC=C1C1=COC2=C(O)C(O)=CC=C2C1=O DLXIJJURUIXRFK-UHFFFAOYSA-N 0.000 claims description 2
- GXAPLLMJHZBIPX-UHFFFAOYSA-N Retusine Natural products O1C(=O)C(C)C(C)C(C)(O)C(=O)OCC2CCN3C2C1CC3 GXAPLLMJHZBIPX-UHFFFAOYSA-N 0.000 claims description 2
- 206010040825 Skin depigmentation Diseases 0.000 claims description 2
- 125000003545 alkoxy group Chemical group 0.000 claims description 2
- NDMNOCFEDLHFKY-UHFFFAOYSA-N ethyl 5-(ethoxycarbonyloxyamino)-2-hydroxybenzoate Chemical compound C(C)OC(=O)ONC1=CC(=C(C=C1)O)C(=O)OCC NDMNOCFEDLHFKY-UHFFFAOYSA-N 0.000 claims description 2
- RIKPNWPEMPODJD-UHFFFAOYSA-N formononetin Natural products C1=CC(OC)=CC=C1C1=COC2=CC=CC=C2C1=O RIKPNWPEMPODJD-UHFFFAOYSA-N 0.000 claims description 2
- MZERYTHMEZCPQG-UHFFFAOYSA-N junipegenin-B Natural products C1=C(OC)C(OC)=CC=C1C1=COC2=CC(O)=C(OC)C(O)=C2C1=O MZERYTHMEZCPQG-UHFFFAOYSA-N 0.000 claims description 2
- 230000001530 keratinolytic effect Effects 0.000 claims description 2
- 239000002207 metabolite Substances 0.000 claims description 2
- UYLQOGTYNFVQQX-UHFFFAOYSA-N psi-tectorigenin Natural products COC1=C(O)C=C(O)C(C2=O)=C1OC=C2C1=CC=C(O)C=C1 UYLQOGTYNFVQQX-UHFFFAOYSA-N 0.000 claims description 2
- 229930008691 retusin Natural products 0.000 claims description 2
- OYUJPVCKGSEYDD-UHFFFAOYSA-N tectorigenin Natural products COc1c(O)cc2OCC(C(=O)c2c1O)c1ccc(O)cc1 OYUJPVCKGSEYDD-UHFFFAOYSA-N 0.000 claims description 2
- NZVLHOXXOSELRF-UHFFFAOYSA-N 3-(3,5-dihydroxy-4-methoxyphenyl)-5,7-dihydroxychromen-4-one Chemical compound C1=C(O)C(OC)=C(O)C=C1C1=COC2=CC(O)=CC(O)=C2C1=O NZVLHOXXOSELRF-UHFFFAOYSA-N 0.000 claims 2
- 150000002515 isoflavone derivatives Chemical group 0.000 claims 1
- 239000013543 active substance Substances 0.000 abstract description 8
- 229930013032 isoflavonoid Natural products 0.000 abstract description 2
- 150000003817 isoflavonoid derivatives Chemical class 0.000 abstract description 2
- 235000012891 isoflavonoids Nutrition 0.000 abstract description 2
- 238000004042 decolorization Methods 0.000 abstract 1
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerol Natural products OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 14
- 210000003491 skin Anatomy 0.000 description 13
- 239000012071 phase Substances 0.000 description 11
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 9
- 125000000217 alkyl group Chemical group 0.000 description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
- 239000000463 material Substances 0.000 description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- 239000000839 emulsion Substances 0.000 description 6
- 239000003921 oil Substances 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 229910052799 carbon Inorganic materials 0.000 description 5
- 125000004432 carbon atom Chemical group C* 0.000 description 5
- 235000019198 oils Nutrition 0.000 description 5
- LXAHHHIGZXPRKQ-UHFFFAOYSA-N 5-fluoro-2-methylpyridine Chemical compound CC1=CC=C(F)C=N1 LXAHHHIGZXPRKQ-UHFFFAOYSA-N 0.000 description 4
- 241001597008 Nomeidae Species 0.000 description 4
- 230000002421 anti-septic effect Effects 0.000 description 4
- 150000002148 esters Chemical class 0.000 description 4
- 239000012530 fluid Substances 0.000 description 4
- MNWFXJYAOYHMED-UHFFFAOYSA-N heptanoic acid Chemical compound CCCCCCC(O)=O MNWFXJYAOYHMED-UHFFFAOYSA-N 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- 125000006353 oxyethylene group Chemical group 0.000 description 4
- 239000008363 phosphate buffer Substances 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- 235000020712 soy bean extract Nutrition 0.000 description 4
- 235000015112 vegetable and seed oil Nutrition 0.000 description 4
- 239000008158 vegetable oil Substances 0.000 description 4
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 229920002125 Sokalan® Polymers 0.000 description 3
- 239000002671 adjuvant Substances 0.000 description 3
- BLFLLBZGZJTVJG-UHFFFAOYSA-N benzocaine Chemical compound CCOC(=O)C1=CC=C(N)C=C1 BLFLLBZGZJTVJG-UHFFFAOYSA-N 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 239000007957 coemulsifier Substances 0.000 description 3
- 235000014113 dietary fatty acids Nutrition 0.000 description 3
- MTHSVFCYNBDYFN-UHFFFAOYSA-N diethylene glycol Chemical compound OCCOCCO MTHSVFCYNBDYFN-UHFFFAOYSA-N 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 239000003995 emulsifying agent Substances 0.000 description 3
- 239000003925 fat Substances 0.000 description 3
- 239000000194 fatty acid Substances 0.000 description 3
- 229930195729 fatty acid Natural products 0.000 description 3
- 150000004665 fatty acids Chemical class 0.000 description 3
- 239000003349 gelling agent Substances 0.000 description 3
- 208000000069 hyperpigmentation Diseases 0.000 description 3
- 230000003810 hyperpigmentation Effects 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- HEOCBCNFKCOKBX-RELGSGGGSA-N (1s,2e,4r)-4,7,7-trimethyl-2-[(4-methylphenyl)methylidene]bicyclo[2.2.1]heptan-3-one Chemical compound C1=CC(C)=CC=C1\C=C/1C(=O)[C@]2(C)CC[C@H]\1C2(C)C HEOCBCNFKCOKBX-RELGSGGGSA-N 0.000 description 2
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 241000233866 Fungi Species 0.000 description 2
- QIGBRXMKCJKVMJ-UHFFFAOYSA-N Hydroquinone Chemical compound OC1=CC=C(O)C=C1 QIGBRXMKCJKVMJ-UHFFFAOYSA-N 0.000 description 2
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 2
- 206010024380 Leukoderma Diseases 0.000 description 2
- 208000003351 Melanosis Diseases 0.000 description 2
- YBGZDTIWKVFICR-JLHYYAGUSA-N Octyl 4-methoxycinnamic acid Chemical compound CCCCC(CC)COC(=O)\C=C\C1=CC=C(OC)C=C1 YBGZDTIWKVFICR-JLHYYAGUSA-N 0.000 description 2
- HVUMOYIDDBPOLL-XWVZOOPGSA-N Sorbitan monostearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O HVUMOYIDDBPOLL-XWVZOOPGSA-N 0.000 description 2
- 235000021355 Stearic acid Nutrition 0.000 description 2
- RIQIJXOWVAHQES-UNAKLNRMSA-N Tocoretinate Chemical compound C([C@@](OC1=C(C)C=2C)(C)CCC[C@H](C)CCC[C@H](C)CCCC(C)C)CC1=C(C)C=2OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C RIQIJXOWVAHQES-UNAKLNRMSA-N 0.000 description 2
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 2
- HLLPKVARTYKIJB-MCQPFKOBSA-N [(2r,3s,4s,5r,6r)-6-[(2s,3s,4s,5r)-3,4-dihydroxy-2,5-bis(octadecanoyloxymethyl)oxolan-2-yl]oxy-3,4,5-trihydroxyoxan-2-yl]methyl octadecanoate Chemical compound O[C@H]1[C@H](O)[C@@H](COC(=O)CCCCCCCCCCCCCCCCC)O[C@@]1(COC(=O)CCCCCCCCCCCCCCCCC)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](COC(=O)CCCCCCCCCCCCCCCCC)O1 HLLPKVARTYKIJB-MCQPFKOBSA-N 0.000 description 2
- 239000002585 base Substances 0.000 description 2
- 239000011324 bead Substances 0.000 description 2
- 229960001716 benzalkonium Drugs 0.000 description 2
- CYDRXTMLKJDRQH-UHFFFAOYSA-N benzododecinium Chemical compound CCCCCCCCCCCC[N+](C)(C)CC1=CC=CC=C1 CYDRXTMLKJDRQH-UHFFFAOYSA-N 0.000 description 2
- 239000010238 camphora Substances 0.000 description 2
- 229940025250 camphora Drugs 0.000 description 2
- 229960001631 carbomer Drugs 0.000 description 2
- 239000004359 castor oil Substances 0.000 description 2
- 235000019438 castor oil Nutrition 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000004927 clay Substances 0.000 description 2
- UVCJGUGAGLDPAA-UHFFFAOYSA-N ensulizole Chemical compound N1C2=CC(S(=O)(=O)O)=CC=C2N=C1C1=CC=CC=C1 UVCJGUGAGLDPAA-UHFFFAOYSA-N 0.000 description 2
- 229960000655 ensulizole Drugs 0.000 description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
- 230000001815 facial effect Effects 0.000 description 2
- 229930003935 flavonoid Natural products 0.000 description 2
- 235000017173 flavonoids Nutrition 0.000 description 2
- 150000002215 flavonoids Chemical class 0.000 description 2
- 125000002791 glucosyl group Chemical group C1([C@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 2
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 2
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 2
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- BJRNKVDFDLYUGJ-RMPHRYRLSA-N hydroquinone O-beta-D-glucopyranoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC=C(O)C=C1 BJRNKVDFDLYUGJ-RMPHRYRLSA-N 0.000 description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- QUAMTGJKVDWJEQ-UHFFFAOYSA-N octabenzone Chemical compound OC1=CC(OCCCCCCCC)=CC=C1C(=O)C1=CC=CC=C1 QUAMTGJKVDWJEQ-UHFFFAOYSA-N 0.000 description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 2
- 235000014593 oils and fats Nutrition 0.000 description 2
- DXGLGDHPHMLXJC-UHFFFAOYSA-N oxybenzone Chemical compound OC1=CC(OC)=CC=C1C(=O)C1=CC=CC=C1 DXGLGDHPHMLXJC-UHFFFAOYSA-N 0.000 description 2
- 229960001173 oxybenzone Drugs 0.000 description 2
- 239000000049 pigment Substances 0.000 description 2
- 239000000419 plant extract Substances 0.000 description 2
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N squalane Chemical compound CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 2
- 239000008117 stearic acid Substances 0.000 description 2
- CXVGEDCSTKKODG-UHFFFAOYSA-N sulisobenzone Chemical compound C1=C(S(O)(=O)=O)C(OC)=CC(O)=C1C(=O)C1=CC=CC=C1 CXVGEDCSTKKODG-UHFFFAOYSA-N 0.000 description 2
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- WBYWAXJHAXSJNI-VOTSOKGWSA-M trans-cinnamate Chemical compound [O-]C(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-M 0.000 description 2
- 229950010156 tretinoin tocoferil Drugs 0.000 description 2
- 239000010913 used oil Substances 0.000 description 2
- 210000003934 vacuole Anatomy 0.000 description 2
- OIQXFRANQVWXJF-QBFSEMIESA-N (2z)-2-benzylidene-4,7,7-trimethylbicyclo[2.2.1]heptan-3-one Chemical class CC1(C)C2CCC1(C)C(=O)\C2=C/C1=CC=CC=C1 OIQXFRANQVWXJF-QBFSEMIESA-N 0.000 description 1
- DNIAPMSPPWPWGF-GSVOUGTGSA-N (R)-(-)-Propylene glycol Chemical compound C[C@@H](O)CO DNIAPMSPPWPWGF-GSVOUGTGSA-N 0.000 description 1
- DSSYKIVIOFKYAU-XCBNKYQSSA-N (R)-camphor Chemical compound C1C[C@@]2(C)C(=O)C[C@@H]1C2(C)C DSSYKIVIOFKYAU-XCBNKYQSSA-N 0.000 description 1
- JYEUMXHLPRZUAT-UHFFFAOYSA-N 1,2,3-triazine Chemical compound C1=CN=NN=C1 JYEUMXHLPRZUAT-UHFFFAOYSA-N 0.000 description 1
- OTKCEEWUXHVZQI-UHFFFAOYSA-N 1,2-diphenylethanone Chemical compound C=1C=CC=CC=1C(=O)CC1=CC=CC=C1 OTKCEEWUXHVZQI-UHFFFAOYSA-N 0.000 description 1
- NWGAAWUUGRXXSC-UHFFFAOYSA-N 1-(2-hydroxypropoxy)propan-2-yl 2-hydroxybenzoate Chemical compound CC(O)COCC(C)OC(=O)C1=CC=CC=C1O NWGAAWUUGRXXSC-UHFFFAOYSA-N 0.000 description 1
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 1
- HYZJCKYKOHLVJF-UHFFFAOYSA-N 1H-benzimidazole Chemical compound C1=CC=C2NC=NC2=C1 HYZJCKYKOHLVJF-UHFFFAOYSA-N 0.000 description 1
- LIHSOKFARJWASE-UHFFFAOYSA-N 1H-imidazole imidazolidine Chemical compound N1CNCC1.N1C=NC=C1 LIHSOKFARJWASE-UHFFFAOYSA-N 0.000 description 1
- MEZZCSHVIGVWFI-UHFFFAOYSA-N 2,2'-Dihydroxy-4-methoxybenzophenone Chemical compound OC1=CC(OC)=CC=C1C(=O)C1=CC=CC=C1O MEZZCSHVIGVWFI-UHFFFAOYSA-N 0.000 description 1
- WHQOKFZWSDOTQP-UHFFFAOYSA-N 2,3-dihydroxypropyl 4-aminobenzoate Chemical compound NC1=CC=C(C(=O)OCC(O)CO)C=C1 WHQOKFZWSDOTQP-UHFFFAOYSA-N 0.000 description 1
- ZXDDPOHVAMWLBH-UHFFFAOYSA-N 2,4-Dihydroxybenzophenone Chemical compound OC1=CC(O)=CC=C1C(=O)C1=CC=CC=C1 ZXDDPOHVAMWLBH-UHFFFAOYSA-N 0.000 description 1
- LSHGMOIQPURPAK-UHFFFAOYSA-N 2-benzylidene-1,4,7,7-tetramethylbicyclo[2.2.1]heptan-3-one Chemical compound CC1(C)C(C2=O)(C)CCC1(C)C2=CC1=CC=CC=C1 LSHGMOIQPURPAK-UHFFFAOYSA-N 0.000 description 1
- JGUMTYWKIBJSTN-UHFFFAOYSA-N 2-ethylhexyl 4-[[4,6-bis[4-(2-ethylhexoxycarbonyl)anilino]-1,3,5-triazin-2-yl]amino]benzoate Chemical compound C1=CC(C(=O)OCC(CC)CCCC)=CC=C1NC1=NC(NC=2C=CC(=CC=2)C(=O)OCC(CC)CCCC)=NC(NC=2C=CC(=CC=2)C(=O)OCC(CC)CCCC)=N1 JGUMTYWKIBJSTN-UHFFFAOYSA-N 0.000 description 1
- OSCJHTSDLYVCQC-UHFFFAOYSA-N 2-ethylhexyl 4-[[4-[4-(tert-butylcarbamoyl)anilino]-6-[4-(2-ethylhexoxycarbonyl)anilino]-1,3,5-triazin-2-yl]amino]benzoate Chemical compound C1=CC(C(=O)OCC(CC)CCCC)=CC=C1NC1=NC(NC=2C=CC(=CC=2)C(=O)NC(C)(C)C)=NC(NC=2C=CC(=CC=2)C(=O)OCC(CC)CCCC)=N1 OSCJHTSDLYVCQC-UHFFFAOYSA-N 0.000 description 1
- WSSJONWNBBTCMG-UHFFFAOYSA-N 2-hydroxybenzoic acid (3,3,5-trimethylcyclohexyl) ester Chemical compound C1C(C)(C)CC(C)CC1OC(=O)C1=CC=CC=C1O WSSJONWNBBTCMG-UHFFFAOYSA-N 0.000 description 1
- ORWUQAQITKSSRZ-UHFFFAOYSA-N 2-hydroxyethyl 4-[bis[2-(2-hydroxyethoxy)ethyl]amino]benzoate Chemical compound OCCOCCN(CCOCCO)C1=CC=C(C(=O)OCCO)C=C1 ORWUQAQITKSSRZ-UHFFFAOYSA-N 0.000 description 1
- NGBWXSKJSOOOAD-UHFFFAOYSA-N 2h-benzotriazole;2-butyl-3,4,5,6-tetramethylphenol Chemical compound C1=CC=CC2=NNN=C21.CCCCC1=C(C)C(C)=C(C)C(C)=C1O NGBWXSKJSOOOAD-UHFFFAOYSA-N 0.000 description 1
- QOXOZONBQWIKDA-UHFFFAOYSA-N 3-hydroxypropyl Chemical group [CH2]CCO QOXOZONBQWIKDA-UHFFFAOYSA-N 0.000 description 1
- KKJKXQYVUVWWJP-JLHYYAGUSA-N 4-[(e)-(4,7,7-trimethyl-3-oxo-2-bicyclo[2.2.1]heptanylidene)methyl]benzenesulfonic acid Chemical compound CC1(C)C2CCC1(C)C(=O)\C2=C\C1=CC=C(S(O)(=O)=O)C=C1 KKJKXQYVUVWWJP-JLHYYAGUSA-N 0.000 description 1
- ALYNCZNDIQEVRV-UHFFFAOYSA-N 4-aminobenzoic acid Chemical compound NC1=CC=C(C(O)=O)C=C1 ALYNCZNDIQEVRV-UHFFFAOYSA-N 0.000 description 1
- VTQVLCXOOIFPBB-UHFFFAOYSA-N 4-ethyl-5-hexyl-1H-triazin-6-one Chemical compound C(C)C1=C(C(NN=N1)=O)CCCCCC VTQVLCXOOIFPBB-UHFFFAOYSA-N 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-M Acrylate Chemical compound [O-]C(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-M 0.000 description 1
- TWCMVXMQHSVIOJ-UHFFFAOYSA-N Aglycone of yadanzioside D Natural products COC(=O)C12OCC34C(CC5C(=CC(O)C(O)C5(C)C3C(O)C1O)C)OC(=O)C(OC(=O)C)C24 TWCMVXMQHSVIOJ-UHFFFAOYSA-N 0.000 description 1
- 208000037259 Amyloid Plaque Diseases 0.000 description 1
- PLMKQQMDOMTZGG-UHFFFAOYSA-N Astrantiagenin E-methylester Natural products CC12CCC(O)C(C)(CO)C1CCC1(C)C2CC=C2C3CC(C)(C)CCC3(C(=O)OC)CCC21C PLMKQQMDOMTZGG-UHFFFAOYSA-N 0.000 description 1
- 241000195940 Bryophyta Species 0.000 description 1
- QAVFQWKQJMQWLE-UHFFFAOYSA-N C1=CC=C2OC=CC2=C1.C1=CC=C2C(=O)C=COC2=C1 Chemical compound C1=CC=C2OC=CC2=C1.C1=CC=C2C(=O)C=COC2=C1 QAVFQWKQJMQWLE-UHFFFAOYSA-N 0.000 description 1
- 206010008570 Chloasma Diseases 0.000 description 1
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 description 1
- XMSXQFUHVRWGNA-UHFFFAOYSA-N Decamethylcyclopentasiloxane Chemical compound C[Si]1(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O1 XMSXQFUHVRWGNA-UHFFFAOYSA-N 0.000 description 1
- SNRUBQQJIBEYMU-UHFFFAOYSA-N Dodecane Natural products CCCCCCCCCCCC SNRUBQQJIBEYMU-UHFFFAOYSA-N 0.000 description 1
- AFSDNFLWKVMVRB-UHFFFAOYSA-N Ellagic acid Chemical compound OC1=C(O)C(OC2=O)=C3C4=C2C=C(O)C(O)=C4OC(=O)C3=C1 AFSDNFLWKVMVRB-UHFFFAOYSA-N 0.000 description 1
- ATJXMQHAMYVHRX-CPCISQLKSA-N Ellagic acid Natural products OC1=C(O)[C@H]2OC(=O)c3cc(O)c(O)c4OC(=O)C(=C1)[C@H]2c34 ATJXMQHAMYVHRX-CPCISQLKSA-N 0.000 description 1
- 229920002079 Ellagic acid Polymers 0.000 description 1
- FMRHJJZUHUTGKE-UHFFFAOYSA-N Ethylhexyl salicylate Chemical compound CCCCC(CC)COC(=O)C1=CC=CC=C1O FMRHJJZUHUTGKE-UHFFFAOYSA-N 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- JFHCDEYLWGVZMX-CMDGGOBGSA-N Isoamyl cinnamate Chemical compound CC(C)CCOC(=O)\C=C\C1=CC=CC=C1 JFHCDEYLWGVZMX-CMDGGOBGSA-N 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 description 1
- WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 description 1
- 206010071308 Melanocytic hyperplasia Diseases 0.000 description 1
- 240000000249 Morus alba Species 0.000 description 1
- 235000008708 Morus alba Nutrition 0.000 description 1
- HFEQJOALZMHGHG-UHFFFAOYSA-N N1=NNC(C=C1)=O.C(CCC)(=O)NC(CCCCC)(CC)CC Chemical compound N1=NNC(C=C1)=O.C(CCC)(=O)NC(CCCCC)(CC)CC HFEQJOALZMHGHG-UHFFFAOYSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- WYWZRNAHINYAEF-UHFFFAOYSA-N Padimate O Chemical compound CCCCC(CC)COC(=O)C1=CC=C(N(C)C)C=C1 WYWZRNAHINYAEF-UHFFFAOYSA-N 0.000 description 1
- 244000025272 Persea americana Species 0.000 description 1
- 235000008673 Persea americana Nutrition 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 239000004721 Polyphenylene oxide Substances 0.000 description 1
- 241000632296 Scutellaria lateriflora Species 0.000 description 1
- GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 description 1
- 206010047642 Vitiligo Diseases 0.000 description 1
- YIMQCDZDWXUDCA-UHFFFAOYSA-N [4-(hydroxymethyl)cyclohexyl]methanol Chemical compound OCC1CCC(CO)CC1 YIMQCDZDWXUDCA-UHFFFAOYSA-N 0.000 description 1
- 239000002250 absorbent Substances 0.000 description 1
- 230000002745 absorbent Effects 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 229920006243 acrylic copolymer Polymers 0.000 description 1
- 229920000800 acrylic rubber Polymers 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 150000001336 alkenes Chemical class 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000010775 animal oil Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 229960000271 arbutin Drugs 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- XNEFYCZVKIDDMS-UHFFFAOYSA-N avobenzone Chemical compound C1=CC(OC)=CC=C1C(=O)CC(=O)C1=CC=C(C(C)(C)C)C=C1 XNEFYCZVKIDDMS-UHFFFAOYSA-N 0.000 description 1
- 125000002511 behenyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- XVAMCHGMPYWHNL-UHFFFAOYSA-N bemotrizinol Chemical compound OC1=CC(OCC(CC)CCCC)=CC=C1C1=NC(C=2C=CC(OC)=CC=2)=NC(C=2C(=CC(OCC(CC)CCCC)=CC=2)O)=N1 XVAMCHGMPYWHNL-UHFFFAOYSA-N 0.000 description 1
- 229960004101 bemotrizinol Drugs 0.000 description 1
- 239000000440 bentonite Substances 0.000 description 1
- 229910000278 bentonite Inorganic materials 0.000 description 1
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 1
- 229960005274 benzocaine Drugs 0.000 description 1
- IANQTJSKSUMEQM-UHFFFAOYSA-N benzofuran Natural products C1=CC=C2OC=CC2=C1 IANQTJSKSUMEQM-UHFFFAOYSA-N 0.000 description 1
- RWCCWEUUXYIKHB-UHFFFAOYSA-N benzophenone Chemical compound C=1C=CC=CC=1C(=O)C1=CC=CC=C1 RWCCWEUUXYIKHB-UHFFFAOYSA-N 0.000 description 1
- 239000012965 benzophenone Substances 0.000 description 1
- 229940111759 benzophenone-2 Drugs 0.000 description 1
- 229940079894 benzophenone-9 Drugs 0.000 description 1
- QRUDEWIWKLJBPS-UHFFFAOYSA-N benzotriazole Chemical compound C1=CC=C2N[N][N]C2=C1 QRUDEWIWKLJBPS-UHFFFAOYSA-N 0.000 description 1
- 239000012964 benzotriazole Substances 0.000 description 1
- WXNRYSGJLQFHBR-UHFFFAOYSA-N bis(2,4-dihydroxyphenyl)methanone Chemical compound OC1=CC(O)=CC=C1C(=O)C1=CC=C(O)C=C1O WXNRYSGJLQFHBR-UHFFFAOYSA-N 0.000 description 1
- SODJJEXAWOSSON-UHFFFAOYSA-N bis(2-hydroxy-4-methoxyphenyl)methanone Chemical compound OC1=CC(OC)=CC=C1C(=O)C1=CC=C(OC)C=C1O SODJJEXAWOSSON-UHFFFAOYSA-N 0.000 description 1
- YEAYGXLRPMKZBP-KQGICBIGSA-N bis(2-hydroxyethyl)azanium;(e)-3-(4-methoxyphenyl)prop-2-enoate Chemical compound OCCNCCO.COC1=CC=C(\C=C\C(O)=O)C=C1 YEAYGXLRPMKZBP-KQGICBIGSA-N 0.000 description 1
- FQUNFJULCYSSOP-UHFFFAOYSA-N bisoctrizole Chemical compound N1=C2C=CC=CC2=NN1C1=CC(C(C)(C)CC(C)(C)C)=CC(CC=2C(=C(C=C(C=2)C(C)(C)CC(C)(C)C)N2N=C3C=CC=CC3=N2)O)=C1O FQUNFJULCYSSOP-UHFFFAOYSA-N 0.000 description 1
- 239000008366 buffered solution Substances 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000004203 carnauba wax Substances 0.000 description 1
- 229960000541 cetyl alcohol Drugs 0.000 description 1
- FZFAMSAMCHXGEF-UHFFFAOYSA-N chloro formate Chemical compound ClOC=O FZFAMSAMCHXGEF-UHFFFAOYSA-N 0.000 description 1
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol group Chemical group [C@@H]1(CC[C@H]2[C@@H]3CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C)[C@H](C)CCCC(C)C HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 1
- 229940114081 cinnamate Drugs 0.000 description 1
- 229930016911 cinnamic acid Natural products 0.000 description 1
- 235000013985 cinnamic acid Nutrition 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 229930016834 coumestan Natural products 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 229940086555 cyclomethicone Drugs 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 239000007854 depigmenting agent Substances 0.000 description 1
- NZZIMKJIVMHWJC-UHFFFAOYSA-N dibenzoylmethane Chemical class C=1C=CC=CC=1C(=O)CC(=O)C1=CC=CC=C1 NZZIMKJIVMHWJC-UHFFFAOYSA-N 0.000 description 1
- 229960005215 dichloroacetic acid Drugs 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- GLCJMPWWQKKJQZ-UHFFFAOYSA-L disodium;2-[4-(4,6-disulfonato-1h-benzimidazol-2-yl)phenyl]-1h-benzimidazole-4,6-disulfonate;hydron Chemical compound [Na+].[Na+].C1=C(S(O)(=O)=O)C=C2NC(C3=CC=C(C=C3)C3=NC4=C(C=C(C=C4N3)S(=O)(=O)O)S([O-])(=O)=O)=NC2=C1S([O-])(=O)=O GLCJMPWWQKKJQZ-UHFFFAOYSA-L 0.000 description 1
- QDCHWIWENYCPIL-UHFFFAOYSA-L disodium;4-hydroxy-5-(2-hydroxy-4-methoxy-5-sulfonatobenzoyl)-2-methoxybenzenesulfonate Chemical compound [Na+].[Na+].C1=C(S([O-])(=O)=O)C(OC)=CC(O)=C1C(=O)C1=CC(S([O-])(=O)=O)=C(OC)C=C1O QDCHWIWENYCPIL-UHFFFAOYSA-L 0.000 description 1
- 125000003438 dodecyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- HUVYTMDMDZRHBN-UHFFFAOYSA-N drometrizole trisiloxane Chemical compound C[Si](C)(C)O[Si](C)(O[Si](C)(C)C)CC(C)CC1=CC(C)=CC(N2N=C3C=CC=CC3=N2)=C1O HUVYTMDMDZRHBN-UHFFFAOYSA-N 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 229960002852 ellagic acid Drugs 0.000 description 1
- 235000004132 ellagic acid Nutrition 0.000 description 1
- 229960004697 enzacamene Drugs 0.000 description 1
- 239000000262 estrogen Substances 0.000 description 1
- 229940011871 estrogen Drugs 0.000 description 1
- IAJNXBNRYMEYAZ-UHFFFAOYSA-N ethyl 2-cyano-3,3-diphenylprop-2-enoate Chemical compound C=1C=CC=CC=1C(=C(C#N)C(=O)OCC)C1=CC=CC=C1 IAJNXBNRYMEYAZ-UHFFFAOYSA-N 0.000 description 1
- CBZHHQOZZQEZNJ-UHFFFAOYSA-N ethyl 4-[bis(2-hydroxypropyl)amino]benzoate Chemical compound CCOC(=O)C1=CC=C(N(CC(C)O)CC(C)O)C=C1 CBZHHQOZZQEZNJ-UHFFFAOYSA-N 0.000 description 1
- 229940068171 ethyl hexyl salicylate Drugs 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 210000004905 finger nail Anatomy 0.000 description 1
- 229930003944 flavone Natural products 0.000 description 1
- 150000002212 flavone derivatives Chemical class 0.000 description 1
- 235000011949 flavones Nutrition 0.000 description 1
- NBVXSUQYWXRMNV-UHFFFAOYSA-N fluoromethane Chemical compound FC NBVXSUQYWXRMNV-UHFFFAOYSA-N 0.000 description 1
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 1
- 235000003969 glutathione Nutrition 0.000 description 1
- 229960003180 glutathione Drugs 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 125000005456 glyceride group Chemical group 0.000 description 1
- 229940075529 glyceryl stearate Drugs 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- PFOARMALXZGCHY-UHFFFAOYSA-N homoegonol Natural products C1=C(OC)C(OC)=CC=C1C1=CC2=CC(CCCO)=CC(OC)=C2O1 PFOARMALXZGCHY-UHFFFAOYSA-N 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 230000000640 hydroxylating effect Effects 0.000 description 1
- 208000013403 hyperactivity Diseases 0.000 description 1
- 150000002462 imidazolines Chemical class 0.000 description 1
- 239000012948 isocyanate Substances 0.000 description 1
- 150000002513 isocyanates Chemical class 0.000 description 1
- NNQSGBRGJHSRFN-UHFFFAOYSA-N isoflavan Chemical compound C1OC2=CC=CC=C2CC1C1=CC=CC=C1 NNQSGBRGJHSRFN-UHFFFAOYSA-N 0.000 description 1
- 235000002324 isoflavanes Nutrition 0.000 description 1
- RTRZOHKLISMNRD-UHFFFAOYSA-N isoflavanone Chemical compound C1OC2=CC=CC=C2C(=O)C1C1=CC=CC=C1 RTRZOHKLISMNRD-UHFFFAOYSA-N 0.000 description 1
- BEJNERDRQOWKJM-UHFFFAOYSA-N kojic acid Chemical compound OCC1=CC(=O)C(O)=CO1 BEJNERDRQOWKJM-UHFFFAOYSA-N 0.000 description 1
- 229960004705 kojic acid Drugs 0.000 description 1
- WZNJWVWKTVETCG-UHFFFAOYSA-N kojic acid Natural products OC(=O)C(N)CN1C=CC(=O)C(O)=C1 WZNJWVWKTVETCG-UHFFFAOYSA-N 0.000 description 1
- 125000002463 lignoceryl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 210000002752 melanocyte Anatomy 0.000 description 1
- 230000003101 melanogenic effect Effects 0.000 description 1
- 229940041616 menthol Drugs 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- WBYWAXJHAXSJNI-UHFFFAOYSA-N methyl p-hydroxycinnamate Natural products OC(=O)C=CC1=CC=CC=C1 WBYWAXJHAXSJNI-UHFFFAOYSA-N 0.000 description 1
- 150000005451 methyl sulfates Chemical class 0.000 description 1
- FAARLWTXUUQFSN-UHFFFAOYSA-N methylellagic acid Natural products O1C(=O)C2=CC(O)=C(O)C3=C2C2=C1C(OC)=C(O)C=C2C(=O)O3 FAARLWTXUUQFSN-UHFFFAOYSA-N 0.000 description 1
- 229950000081 metilsulfate Drugs 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 125000002819 montanyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 235000011929 mousse Nutrition 0.000 description 1
- 125000001802 myricyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000002088 nanocapsule Substances 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- 239000002077 nanosphere Substances 0.000 description 1
- 229920001206 natural gum Polymers 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 125000001400 nonyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 230000037311 normal skin Effects 0.000 description 1
- 230000000474 nursing effect Effects 0.000 description 1
- RWZYAGGXGHYGMB-UHFFFAOYSA-N o-aminobenzenecarboxylic acid Natural products NC1=CC=CC=C1C(O)=O RWZYAGGXGHYGMB-UHFFFAOYSA-N 0.000 description 1
- 229960001679 octinoxate Drugs 0.000 description 1
- FMJSMJQBSVNSBF-UHFFFAOYSA-N octocrylene Chemical group C=1C=CC=CC=1C(=C(C#N)C(=O)OCC(CC)CCCC)C1=CC=CC=C1 FMJSMJQBSVNSBF-UHFFFAOYSA-N 0.000 description 1
- 229960000601 octocrylene Drugs 0.000 description 1
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000004533 oil dispersion Substances 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 125000004430 oxygen atom Chemical group O* 0.000 description 1
- BJRNKVDFDLYUGJ-UHFFFAOYSA-N p-hydroxyphenyl beta-D-alloside Natural products OC1C(O)C(O)C(CO)OC1OC1=CC=C(O)C=C1 BJRNKVDFDLYUGJ-UHFFFAOYSA-N 0.000 description 1
- 125000000913 palmityl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 229940032067 peg-20 stearate Drugs 0.000 description 1
- QQVIHTHCMHWDBS-UHFFFAOYSA-N perisophthalic acid Natural products OC(=O)C1=CC=CC(C(O)=O)=C1 QQVIHTHCMHWDBS-UHFFFAOYSA-N 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 208000017983 photosensitivity disease Diseases 0.000 description 1
- 231100000434 photosensitization Toxicity 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- PMJHHCWVYXUKFD-UHFFFAOYSA-N piperylene Natural products CC=CC=C PMJHHCWVYXUKFD-UHFFFAOYSA-N 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 229920000058 polyacrylate Polymers 0.000 description 1
- 229920000570 polyether Polymers 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 239000000583 progesterone congener Substances 0.000 description 1
- XATKDVHSLQMHSY-RMKNXTFCSA-N propan-2-yl (e)-3-(4-methoxyphenyl)prop-2-enoate Chemical compound COC1=CC=C(\C=C\C(=O)OC(C)C)C=C1 XATKDVHSLQMHSY-RMKNXTFCSA-N 0.000 description 1
- 239000013558 reference substance Substances 0.000 description 1
- JUVIOZPCNVVQFO-HBGVWJBISA-N rotenone Chemical compound O([C@H](CC1=C2O3)C(C)=C)C1=CC=C2C(=O)[C@@H]1[C@H]3COC2=C1C=C(OC)C(OC)=C2 JUVIOZPCNVVQFO-HBGVWJBISA-N 0.000 description 1
- 150000003902 salicylic acid esters Chemical class 0.000 description 1
- 231100000241 scar Toxicity 0.000 description 1
- 229920002545 silicone oil Polymers 0.000 description 1
- LUPNKHXLFSSUGS-UHFFFAOYSA-M sodium;2,2-dichloroacetate Chemical compound [Na+].[O-]C(=O)C(Cl)Cl LUPNKHXLFSSUGS-UHFFFAOYSA-M 0.000 description 1
- KJCLYACXIWMFCC-UHFFFAOYSA-M sodium;5-benzoyl-4-hydroxy-2-methoxybenzenesulfonate Chemical compound [Na+].C1=C(S([O-])(=O)=O)C(OC)=CC(O)=C1C(=O)C1=CC=CC=C1 KJCLYACXIWMFCC-UHFFFAOYSA-M 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 235000013599 spices Nutrition 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 125000004079 stearyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 229960000368 sulisobenzone Drugs 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 150000003918 triazines Chemical class 0.000 description 1
- 125000002889 tridecyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- UEVAMYPIMMOEFW-UHFFFAOYSA-N trolamine salicylate Chemical compound OCCN(CCO)CCO.OC(=O)C1=CC=CC=C1O UEVAMYPIMMOEFW-UHFFFAOYSA-N 0.000 description 1
- 229960004441 tyrosine Drugs 0.000 description 1
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
- A61K8/42—Amides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/02—Preparations for care of the skin for chemically bleaching or whitening the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
- A61K8/41—Amines
- A61K8/411—Aromatic amines, i.e. where the amino group is directly linked to the aromatic nucleus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
- A61K8/41—Amines
- A61K8/415—Aminophenols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
- A61K8/4973—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom
- A61K8/498—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom having 6-membered rings or their condensed derivatives, e.g. coumarin
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Birds (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Cosmetics (AREA)
Abstract
本发明涉及一种组合物,该组合物含有存在于生理学上可接受的介质中的至少一种氨基苯酚衍生物和至少一种异黄酮类物质。本发明还涉及该组合物在制备用于人皮肤脱色素和/或漂白的制剂中的应用。活性成分的这些组合在皮肤脱色素或漂白方面显示协同作用。
Description
技术领域
本发明涉及一种组合物，该组合物含有存在于生理学上可接受的介质中的至少一种氨基苯酚衍生物和至少一种异黄酮类物质(isoflavonoid)；本发明还涉及该组合物在用于脱色素和/或漂白人皮肤的化妆品和/或皮肤病学制剂中的应用。
背景技术
若干年来，在提出无害的高效局部脱色素物质方面，人们已经作出了许多尝试。最特别需要的是这些高效物质可以用于治疗：由黑素细胞活动过多(例如自发性黑斑病、妊娠期间(“妊娠斑”或褐黄斑)或雌孕激素避孕期间)引起的区域性色素沉着过度、由良性黑素细胞增生和机能亢进引起的局部色素沉着过度(例如被称为光化性雀斑的老年斑、偶发性色素沉着过度或脱色素，其可能由光致敏或损害后结瘢引起)，还有某些白斑病，例如白癜风。对于这些疾病(其中结瘢可以引起伤疤，从而使皮肤更白)和白斑病来说，由于不能使受损害的皮肤进行色素修复，为了使皮肤具有总体均匀的白色，可以把残余的正常皮肤区域进行脱色素处理。
现有技术已经公开了各种脱色素试剂。
在最公知的技术中可以提到的物质有：对苯二酚及其衍生物例如熊果甙及其酯；抗坏血酸及其衍生物特别是葡萄糖基化衍生物；曲酸及其酯；鞣花酸及其衍生物；植物提取物，特别是甘草、桑树或美黄芩提取物；还有谷胱甘肽、半胱氨酸及其前体物质。
另外，本申请人已经证明：某些氨基苯酚衍生物即使在低浓度下也具有抑制黑素生成的活性，并且其不显示任何的细胞毒性(WO99/10318)。
本申请人现已令人意外地发现：联合应用氨基苯酚衍生物和异黄酮类物质具有比单独应用这些化合物更优越的脱色素性能。换句话说，联合应用这两类化合物能加强这些化合物的效果，使这些化合物在皮肤漂白和/或脱色素方面产生协同作用。
异黄酮类属于黄酮类的一亚类，由3-苯基苯并二氢吡喃骨架构成，其可以具有各种取代基，并可以有不同的氧化程度。与黄酮相比，异黄酮仅仅存在于非常有限种类的植物中。
术语“异黄酮类”包括若干类化合物，其中可以提到的有：异黄酮、异黄烷酮、类鱼藤酮、pterocarpans、异黄烷、异黄烷-3-烯、3-芳基香豆素、3-芳基-4-羟基香豆素、coumestans、苯并呋喃色酮(coumaronochromones)、α-甲基脱氧苯偶姻或2-芳基苯并呋喃。在这方面，对异黄酮类、其分析方法和来源作一个完全的回顾，可以参照：P.M.Dewich编著的The Flavonoids第5章“异黄酮类”，由Harbone出版，第125-157页(1998)。
诚然，已知某些异黄酮类可以作为脱色素试剂。然而，据本申请人所知，尚没有关于把异黄酮类与氨基苯酚衍生物结合的技术。
发明内容
因此，本发明的一个主题是提供一种组合物，所述组合物含有存在于生理上可接受的介质中的至少一种氨基苯酚衍生物和至少一种异黄酮类。
术语“生理上可接受的介质”意指适合于局部给药至皮肤或其覆盖物的介质，即其能够与皮肤或指甲相容。
本发明另一个主题是该组合物作为皮肤脱色素和/或漂白制剂的化妆应用。
本发明再一个主题是该组合物在制备用于人皮肤脱色和/或漂白制剂中的应用。
本发明还涉及用于人皮肤脱色和/或漂白的化妆方法，其包括将本发明的组合物施用于所述皮肤。
本发明的氨基苯酚化合物优选下式(I)化合物：
其中：
R代表氢原子或-COR2基团，
R2代表的基团选自：饱和或不饱和、直链、环状或支链C1-C30任选羟基化的烷基或烷氧基基团，
R1选自下式(a)、(b)或(c)的基团：
(a)-CO-NR3R4
(b)-COOR5
(c)-SO2-R5
其中R3代表氢原子或直链或支链、饱和或不饱和、任选羟基化的C1-C6烷基，
R4代表氢原子，或者选自饱和或不饱和、直链、支链或环状的任选羟基化的C1-C30烷基，
R5代表的基团选自饱和或不饱和、直链、环状或支链、任选羟基化的C1-C30烷基，
以及其于生理上可接受的酸或碱的加成盐。
这些化合物的优点在于其容易获得。它们特别容易由下列反应得到：氨基苯酚与活性化学物质例如咪唑烷(imidazolide)或异氰酸酯(当R1为式(a)基团时)、氯甲酸酯(当R1为式(b)基团时)或磺酰氯(当R1为式(c)基团时)反应。
在那些含有1-30个碳原子的直链或支链烷基中，特别可以提到的有甲基、乙基、丙基、异丙基、丁基、叔丁基、己基、辛基、壬基、2-乙基己基、十二烷基、十三烷基、十六烷基、二十二烷基、十八烷基、二十四烷基、二十六烷基、二十八烷基、三十烷基、2-丁基辛基和2-己基癸基。更特别优选地，所述烷基通常含有1-6个碳原子，可以选自甲基、乙基、丙基、异丙基、叔丁基和己基。
当烷基是不饱和的时，优选含有1个或多个烯不饱和键，例如橙花基、2-壬基-2-丁烯基、6-(1，3-戊二烯基)-2，4，7-十二烷三烯-9-炔基和更优选的烯丙基。
当烷基为环状时，可以特别提到的例子有环己基、胆甾烯基或叔丁基环己基。
当其被羟基化时，所述基团优选含有1-6个碳原子和1-5个羟基。
在单羟基烷基中，优选的基团为优选含有1-3个碳原子的基团，特别是羟甲基、2-羟基乙基或者2-或3-羟基丙基。
在这些多羟基烷基基团中，优选的基团为含有3-6个碳原子和含有2-5个羟基的基团，例如2，3-二羟基丙基、2，3，4-三羟基丁基、2，3，4，5-四羟基戊基和2，3，4，5，6-五羟基己基。
烷氧基化基团为前面含有氧原子的烷基、尤其是如上所述的烷基。
有利地，式(I)氨基苯酚衍生物可以选自符合至少一个下列条件并优选符合全部下列条件的化合物：
-R代表氢原子，
-苯基上的-OR位于邻位，或者有利地位于对位，
-R1选自式(a)或(b)的基团。
本发明的式(I)化合物特别选自N-乙氧基羰基-4-氨基苯酚、N-乙氧基羰基-O-乙氧基羰基-4-氨基苯酚、N-胆甾烯基氧-羰基-4-氨基苯酚和N-乙基氨基羰基-4-氨基苯酚。
在本发明中，优选应用N-乙氧基羰基-4-氨基苯酚。
可以从天然来源或合成来源中得到适合用于本发明的异黄酮类。术语“天然来源”意指纯净形式或各种浓度溶液形式的异黄酮，其可以通过从天然来源的物质通常为植物中经各种提取方法得到。术语“合成来源”意指纯净形式或各种浓度的溶液的异黄酮，其可以经化学合成得到。
优选应用天然来源的异黄酮。其中，可以提到的有：黄豆苷、染料木苷、黄豆苷原、芒柄花黄素、cuneatin、染料木黄酮、异樱黄素和樱黄素、cajanin、二羟四氢黄酮、红车轴草素、紫檀酸、junipegeninA、大豆黄素、afrormosin、retusin、鸢尾黄素、irisolidone、牙买黄素，以及其类似物和代谢物，及其混合物。
本发明所优选应用的是异黄酮。该术语既覆盖异黄酮的糖苷配基形式(黄豆苷原、染料木黄酮和大豆黄素)，又覆盖葡萄糖基形式(黄豆苷、染料木苷、大豆苷)。
制备异黄酮的方法特别记载于WO95/10530、WO95/10512、US 5679 806、US 5 554 519、EP 812 837和WO97/26269中。
在特别优选的方式中，优选应用大豆提取物，其具有37％效价的异黄酮，被Maruzen公司以商品名Fujiflavones P40出售。
所述氨基苯酚衍生物和异黄酮类物质以一定量存在于本发明组合物中，这样它们之间协同作用，使该组合物的脱色素效果比含有仅仅一种这些化合物的组合物更优越。
因此，在本发明组合物中，氨基苯酚衍生物特别存在的量为组合物总重的0.01％-10％重量，优选0.5％-3％重量。
作为另一部分，优选异黄酮类物质含量为组合物总重的0.0001％-10％，优选0.001-1％。当然，如果异黄酮类以含有植物提取物的溶液形式存在时，本领域技术人员能够根据本发明调整该溶液在组合物中的含量，从而获得上述浓度范围的异黄酮类物质。
本发明的组合物可以是通常用于局部给药的任何药物形式，其特别是水溶液、水-醇溶液或油溶液、水包油或油包水或多重乳剂、水或油凝胶、液体、糊剂或固体无水产品、借助于小球而分散于水中的油分散体，这些小球可以是聚合物纳米颗粒例如纳米球和纳米胶囊或者更好地为离子型和/或非离子型类脂泡载体。
该组合物多多少少具有流动性，并且其外观可能为白色或彩色膏霜、软膏、乳液、洗剂、浆液、糊剂或奶油冻。其可任选地以气溶胶形式施用于皮肤。其还可以为固体形式，例如棒剂。其可以用作皮肤的护理品和/或化妆品。
通过已知的方式，本发明的组合物还可以含有化妆品中通常的辅料例如亲水性或亲脂性胶凝剂、亲水性或亲脂性活性试剂、防腐剂、抗氧化剂、溶剂、香料、填充剂、掩蔽剂、颜料、气味吸收剂和染料。这些不同辅料的含量是所述领域的常规用量，例如其含量为组合物总重量的0.01％-20％。根据这些物质的性质，可以把这些辅料加入到脂肪相中、水相中、类脂泡中和/或纳米颗粒中。在所有情况下，应该选择这些辅料及其比例从而使本发明的脱色素剂的组合的所需性质不会受到破坏。
当本发明的组合物为乳剂时，脂肪相的比例为组合物总重的5-80％重量比、优选5-50％重量比。在乳剂形式的组合物中，所用的油、乳化剂和辅助乳化剂选自所述领域常用的那些物质。在该组合物中，乳化剂和辅助乳化剂的比例为组合物总重的0.3％-30％重量、优选0.5％-20％重量。
作为本发明所用的油，可以提到的例子为矿物油(液体凡士林)及其酯、植物油(鳄梨油、大豆油)、动物油(羊毛脂)、合成油(全氢化角鲨烯)、硅油(环甲聚硅氧烷(cyclomethicone))和氟油(全氟化聚醚)。脂肪醇(十六烷基醇)、脂肪酸和蜡(巴西棕榈蜡、地蜡)也可以用作脂肪物质。
作为本发明所用的乳化剂和辅助乳化剂，可以提到的例子有例如聚乙二醇脂肪酸酯例如PEG-20硬脂酸酯和甘油脂肪酸酯例如甘油硬脂酸酯。
作为亲水性胶凝剂，特别可以提到的例子为羧乙烯基聚合物卡波姆、丙烯酸共聚物例如丙烯酸酯/烷基丙烯酸酯共聚物、聚丙烯酰胺类、多糖、天然树胶和粘土；至于亲脂性胶凝剂，可以提到的例子为改性粘土例如膨润土、脂肪酸金属盐、疏水性硅胶和聚乙烯类。
作为活性成分，所述组合物优选含有至少一种紫外掩蔽剂和/或一种溶角蛋白剂和/或脱皮剂。
作为可以用于本发明的紫外掩蔽剂，可以提到的例子为(非限制性例子)下述类型的物质(这些名称对应于掩蔽剂的CTFA名称)：
邻氨基苯甲酸酯类，特别是邻氨基苯甲酸薄荷醇酯；二苯甲酮类，特别是二苯甲酮-1、二苯甲酮-3、二苯甲酮-5、二苯甲酮-6、二苯甲酮-8、二苯甲酮-9、二苯甲酮-12和优选地二苯甲酮-2(羟苯甲酮)或二苯甲酮-4(来自于BASF的Uvinul MS40)；亚苄基樟脑类，特别是3-亚苄基-樟脑、亚苄基樟脑磺酸、樟脑苯甲烃铵(benzalkonium)甲基磺酸盐、聚丙酰氨基甲基亚苄基樟脑、对苯二亚甲基二樟脑磺酸和优选地4-甲基亚苄基樟脑(Eusolex 6300，可购自Merck)；苯并咪唑类特别是benzimidazilate(Neo Heliopan AP，可购自Haarmann和Reimer)或苯基苯并咪唑磺酸(Eusolex 232，可购自Merck)；苯并三唑类，特别是drometrizoletrisiloxane或亚甲基双苯并三唑四甲基丁基苯酚(Tinosorb M，购自Ciba)；肉桂酸酯，特别是cinnoxate、DEA甲氧基肉桂酸酯、二异丙基甲基肉桂酸酯、甘油乙基己酸酯二甲氧基肉桂酸酯、异丙基甲氧基肉桂酸酯、异戊基肉桂酸酯和优选ethocrylene(Uvinul N35，可购自BASF)、乙基己基甲氧基肉桂酸酯(Parsol MCX，可购自Hoffmann La Roche)或octocrylene(Uvinul539，可购自BASF)；二苯甲酰基甲烷类特别是丁基甲氧基二苯甲酰基甲烷(Parsol 1789)；咪唑啉类，特别是乙基己基二甲氧基亚苄基二氧咪唑啉；PABAs，特别是乙基二羟基丙基PABA、乙基己基二甲基PABA、甘油基PABA、PABA、PEG-25 PABA和优选地二乙基己基丁酰胺三嗪酮(diethyhexylbutamidotriazone，Uvasorb HEB，可购自3VSigma)，乙基己基三嗪酮(Uvinul T150，可购自BASF)或乙基PABA(苯佐卡因)；水杨酸酯类，特别是二丙二醇水杨酸酯、乙基己基水杨酸酯、水杨酸三甲环己酯或TEA水杨酸酯；三嗪类，特别是aniso三嗪(Tinosorb S，可购自Ciba)。
本发明将通过下列非限制性实施例进行举例说明。
具体实施方式实施例1：本发明化合物的协同作用的举例证明
体外生物学测试(抑制真菌酪氨酸酶)证明了本发明化合物联合应用的脱色素活性。
该测试为：对于各个要测试的脱色素活性试剂，测定其作为时间函数的在波长475nm处的吸收度(光密度OD)。
把这些试剂(以各种浓度)溶解于合适溶剂中，其中所述合适溶剂含有磷酸盐缓冲液、1毫升2.0×10-3M的L-酪氨酸的磷酸盐缓冲液、0.1毫升1.0×10-4M的L-多巴的磷酸盐缓冲液和50微升浓度为1g/L的真菌酪氨酸酶的磷酸盐缓冲溶液，对照品由含同样浓度的磷酸盐缓冲液的溶剂组成。通过下列等式计算抑制百分比：％抑制值＝[DO最大，475nm(对照)-DO最大，475nm(活性试剂)]/DO最大，475nm(对照)×100％
对于各个要研究的活性化合物，测定应该能观察到接近25％抑制值的摩尔浓度(IC理论值)。从而获得相应于单独应用各个活性试剂的浓度C1和C2。然后检测在浓度C1和C2处获得的实际抑制值(IC获取值)。
然后把上述两个活性成分以上述发现的浓度C1和C2相混合。再计算出该混合物的理论抑制百分比(或IC理论值)，其相当于各个化合物所观测到的抑制百分比总数，然后在独立测试所述化合物的同样实验条件下测定获得的抑制百分比(或IC测定值)。
以实施例方式，用N-乙氧基羰基-4-氨基苯酚和含37％效价异黄酮的大豆提取物(Maruzen公司出售的商品Fujiflavone P40)测定的结果如下：活性试剂 浓度C IC理论值(％) IC获取值(％)N-乙氧基羰基-4-氨基苯酚/乙醇 C1＝1.25×10-4M 24.8 23.5大豆提取物(Fujiflavone P40)/DMSO C2＝0.04％ 24.0 31.4活性试剂的组合 IC的预期理论值(％) IC测定值IC(％)N-乙氧基羰基-4-氨基苯酚和大豆提取物 54.9 72.6
明显可以看出：IC测定值远远高于活性试剂混合物的IC理论值。
由于测试准确(为5％左右)，因此明显证明联合应用这两种化合物的协同作用。实施例2：油脂体(Oleosome)-型O/W流体
制备下列组合物，其各组成的重量百分比如下
A相
N-乙氧基羰基-4-氨基苯酚 0.5％
庚酸硬脂醇酯和辛酸硬脂醇酯 5.5％
植物油 11.6％
UVA掩蔽剂 1.9％
环戊硅氧烷 3.7％
蔗糖三硬脂酸酯 2.0％
氧乙烯基化(4EO)脱水山梨醇单硬脂酸酯 1.35％
硬脂酸 1.0％
氧乙烯基化(60EO)氢化蓖麻油 2.5％
醋酸生育酯 0.5％
B相
Fujiflavone P40(Maruzen) 0.1％
防腐剂 0.29％
三乙醇胺 0.50％
EDTA二钠 0.05％
甘油 3.0％
水 加至100.0％
获得一种脸部用漂白流体。
其可以按照下列方式得到：分别把相A和相B加热到65℃，然后将其冷却至室温。然后把B相加入到A相中得到一种W/O型乳液，再将其在高压均化器中进行均化(500b，1-3次)。实施例3：油脂体-型O/W流体
制备下列组合物，其各组成的重量百分比如下
A相
N-乙氧基羰基-4-氨基苯酚 0.5％
庚酸硬脂醇酯和辛酸硬脂醇酯 5.5％
植物油 11.6％
UVA掩蔽剂 1.9％
环戊硅氧烷 3.7％
蔗糖三硬脂酸酯 2.0％
氧乙烯基化(4EO)脱水山梨醇单硬脂酸酯 1.35％
硬脂酸 1.0％
氧乙烯基化(60EO)氢化蓖麻油 2.5％
醋酸生育酯 0.5％
B相
Flavosterone SB(Ichimaru Pharcos) 10.0％
防腐剂 0.29％
三乙醇胺 0.50％
EDTA二钠 0.05％
甘油 3.0％
水 加至100.0％
可以按照实施例2相同的方法得到脸部用漂白流体。
实施例4：脱色素凝胶
A相
UVB掩蔽剂 0.5％
环己硅氧烷 5.0％
B相
Soy Life 150 NGMO(Schouton产品) 0.5％
防腐剂 0.65％
EDTA二钠 0.1％
氢氧化钠 0.11％
甘油 10.0％
乙醇 2.5％
N-乙氧基羰基-4-氨基苯酚 0.5％
水 加至100.0％
C相
卡波姆 0.4％
水 14.6％
以本领域技术人员常规应用的方式可以得到上述凝胶。实施例5：不含表面活性剂的O/W乳剂
A相
N-乙氧基羰基-4-氨基苯酚 0.5％
植物油 12.0％
UVA掩蔽剂 2.0％
UVB掩蔽剂 4.0％
环戊硅氧烷 6.0％
B相
Flavosterone SB(Ichimaru Pharcos) 2.0％
EDTA二钠 0.05％
二甘醇/CHDM/间苯二甲酸酯/SIP共聚物
(Eastman AQ 38S，来自Eastman Chemical) 2.0％
甘油 5.0％
乙醇 10.0％
水 加至100.0％
得到一种漂白霜，其特别适合用于敏感的或活性皮肤。
该漂白霜可以按照本领域技术人员常规应用的方式制备得到。
Claims (16)
1.在生理上可接受的介质中含有至少一种氨基苯酚衍生物和至少一种异黄酮类物质的组合物。
2.权利要求1的组合物，其特征在于氨基苯酚衍生物为下式化合物：其中：
R代表氢原子或-COR2基团，
R2代表的基团选自饱和或不饱和、直链、环状或支链、任选羟基化的C1-C30烷基或烷氧基基团，
R1选自下式(a)、(b)或(c)的基团：
(a)-CO-NR3R4
(b)-COOR5
(c)-SO2-R5
其中R3代表氢原子或直链或支链、饱和或不饱和、任选羟基化的C1-C6烷基，
R4代表氢原子，或者选自饱和或不饱和、直链、环状或支链的任选羟基化的C1-C30烷基。
R5代表的基团选自饱和或不饱和、直链、环状或支链、任选羟基化的C1-C30烷基。
3.权利要求1或2的组合物，其特征在于：所述氨基苯酚衍生物至少满足下列一个条件，优选满足所有下列条件：
-R代表氢原子，
-苯基上的-OR位于邻位，或者有利地位于对位，
-R1选自式(a)或(b)的基团。
4.权利要求1至3任意一项的组合物，其特征在于：所述氨基苯酚衍生物选自N-乙氧基羰基-4-氨基苯酚、N-乙氧基羰基-O-乙氧基羰基-4-氨基苯酚、N-胆甾烯基氧-羰基-4-氨基苯酚和N-乙基氨基羰基-4-氨基苯酚。
5.权利要求1-4任意一项的组合物，其特征在于：所述氨基苯酚衍生物为N-乙氧基羰基-4-氨基苯酚。
6.权利要求1-5任意一项的组合物，其特征在于其含有占组合物总重量0.01％-10％重量的氨基苯酚衍生物。
7.权利要求6的组合物，其特征在于其含有占组合物总重量0.5％-3％重量的氨基苯酚衍生物。
8.权利要求1-7任意一项的组合物，其特征在于其含有占组合物总重0.0001％-10％重量的异黄酮类物质。
9.权利要求8的组合物，其特征在于其含有占组合物总重0.001％-1％重量的异黄酮类。
10.上述任意一项权利要求所述的组合物，其特征在于：所述异黄酮类物质选自天然来源的异黄酮类物质。
11.上述任意一项权利要求所述的组合物，其特征在于所述异黄酮类物质选自：黄豆苷、染料木苷、黄豆苷原、芒柄花黄素、cuneatin、染料木黄酮、异樱黄素和樱黄素、cajanin、二羟四氢黄酮、红车轴草素、紫檀酸、junipegenin A、大豆黄素、afrormosin、retusin、鸢尾黄素、irisolidone和牙买黄素，以及其类似物和代谢物，及其混合物。
12.上述任意一项权利要求所述的组合物，其特征在于所述异黄酮类物质选自异黄酮。
13.权利要求1-12之一所述的组合物，其特征在于：其还含有至少一种UV掩蔽剂和/或至少一种溶角蛋白剂和/或脱皮剂。
14.权利要求1-13任意一项的组合物用作皮肤的脱色素制剂和/或漂白制剂的化妆应用。
15.权利要求1-13任意一项的组合物在制备用于人皮肤脱色素和/或漂白的制剂中的应用。
16.对人皮肤进行脱色素和/或漂白的化妆方法，其包括把权利要求1-13任意一项的组合物施用于皮肤。
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR0014479A FR2816502B1 (fr) | 2000-11-10 | 2000-11-10 | Composition cosmetique comprenant un derive d'aminophenol et un isoflavonoide |
| FR00/14479 | 2000-11-10 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1352935A true CN1352935A (zh) | 2002-06-12 |
| CN1205915C CN1205915C (zh) | 2005-06-15 |
Family
ID=8856310
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB011384263A Expired - Fee Related CN1205915C (zh) | 2000-11-10 | 2001-11-09 | 含有氨基苯酚衍生物和异黄酮类物质的化妆品组合物 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20020107282A1 (zh) |
| EP (1) | EP1205179A1 (zh) |
| JP (1) | JP2002193726A (zh) |
| KR (1) | KR100530199B1 (zh) |
| CN (1) | CN1205915C (zh) |
| FR (1) | FR2816502B1 (zh) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102631362A (zh) * | 2012-01-19 | 2012-08-15 | 中国人民解放军第二军医大学 | 射干异黄酮类化合物在制备预防和治疗紫外线致皮肤损伤药物中的应用 |
| CN103025310A (zh) * | 2010-05-25 | 2013-04-03 | 西姆莱斯有限公司 | 作为皮肤和/或毛发美白活性物的氨基甲酸环己酯化合物 |
| CN113491641A (zh) * | 2020-03-19 | 2021-10-12 | 株式会社Lg生活健康 | 包含葛花苷的组合物 |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE102004060314A1 (de) * | 2004-12-08 | 2006-08-31 | Beiersdorf Ag | Wirkstoffkombinationen aus einem oder mehreren Isoflavonoiden und Carnitin und/oder einem oder mehreren Acyl-Carnitinen |
| BRPI0612705A2 (pt) * | 2005-06-29 | 2010-11-30 | Dsm Ip Assets Bv | composições tópicas compreendendo nanopartìculas de uma isoflavona |
| CN101534810A (zh) * | 2006-10-17 | 2009-09-16 | 株式会社林原生物化学研究所 | 以2-氨基苯酚或其衍生物作为有效成分的抗炎剂 |
| US20100158829A1 (en) * | 2008-12-24 | 2010-06-24 | Conopco, Inc., D/B/A Unilever | Method and Composition for Color Modulation |
| JP5838499B2 (ja) * | 2010-05-25 | 2016-01-06 | シムライズ アーゲー | 皮膚及び／又は毛髪ライトニング活性物質としてのメンチルカルバメート化合物 |
| KR101602629B1 (ko) | 2015-03-30 | 2016-03-11 | 서울대학교산학협력단 | 오로볼을 함유하는 피부 주름 개선용 조성물의 제조방법 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS6019885B2 (ja) * | 1982-06-23 | 1985-05-18 | 一丸フアルコス株式会社 | イソフラボン化合物含有美白化粧料 |
| IL99291A (en) * | 1991-08-23 | 1997-04-15 | Fischer Pharma Ltd | Cosmetic preparations |
| JPH06321752A (ja) * | 1993-05-07 | 1994-11-22 | Kao Corp | 美白剤 |
| JP3271840B2 (ja) * | 1993-12-06 | 2002-04-08 | 花王株式会社 | 新規イソフラボン配糖体及びこれを含有する化粧料 |
| DE4432947C2 (de) * | 1994-09-16 | 1998-04-09 | New Standard Gmbh | Mittel zur Behandlung der Haut und seine Verwendung |
| JPH0977655A (ja) * | 1995-09-14 | 1997-03-25 | Mikimoto Pharmaceut Co Ltd | 皮膚外用剤 |
| FR2767823B1 (fr) * | 1997-08-27 | 1999-10-15 | Oreal | Composes derives d'aminophenol et leur utilisation en cosmetique |
| US5858997A (en) * | 1997-12-04 | 1999-01-12 | Chesebrough-Pond's Usa Co., Division Of Conopco, Inc. | Method and composition for skin lightening |
| JPH11269066A (ja) * | 1998-03-20 | 1999-10-05 | Kao Corp | 経口用美白剤及び美白用食品 |
| FR2796838B1 (fr) * | 1999-07-26 | 2003-05-23 | Oreal | Composition a base de vesicules lamellaires lipidiques incorporant un derive d'amino-phenol, procede de preparation et utilisations |
| FR2802415B1 (fr) * | 1999-12-20 | 2002-07-19 | Oreal | Composition cosmetique comprenant le n-ethyloxycarbonyl-4- amino-phenol et l'arbutine ou ses derives et/ou l'acide ellagique ou ses derives |
-
2000
- 2000-11-10 FR FR0014479A patent/FR2816502B1/fr not_active Expired - Fee Related
-
2001
- 2001-10-19 EP EP01402717A patent/EP1205179A1/fr not_active Withdrawn
- 2001-11-09 JP JP2001345270A patent/JP2002193726A/ja not_active Withdrawn
- 2001-11-09 CN CNB011384263A patent/CN1205915C/zh not_active Expired - Fee Related
- 2001-11-10 KR KR10-2001-0069905A patent/KR100530199B1/ko not_active IP Right Cessation
- 2001-11-13 US US09/986,885 patent/US20020107282A1/en not_active Abandoned
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103025310A (zh) * | 2010-05-25 | 2013-04-03 | 西姆莱斯有限公司 | 作为皮肤和/或毛发美白活性物的氨基甲酸环己酯化合物 |
| CN103025310B (zh) * | 2010-05-25 | 2016-01-27 | 西姆莱斯有限公司 | 作为皮肤和/或毛发美白活性物的氨基甲酸环己酯化合物 |
| CN102631362A (zh) * | 2012-01-19 | 2012-08-15 | 中国人民解放军第二军医大学 | 射干异黄酮类化合物在制备预防和治疗紫外线致皮肤损伤药物中的应用 |
| CN113491641A (zh) * | 2020-03-19 | 2021-10-12 | 株式会社Lg生活健康 | 包含葛花苷的组合物 |
Also Published As
| Publication number | Publication date |
|---|---|
| KR100530199B1 (ko) | 2005-11-22 |
| US20020107282A1 (en) | 2002-08-08 |
| EP1205179A1 (fr) | 2002-05-15 |
| KR20020036764A (ko) | 2002-05-16 |
| FR2816502A1 (fr) | 2002-05-17 |
| FR2816502B1 (fr) | 2003-04-11 |
| JP2002193726A (ja) | 2002-07-10 |
| CN1205915C (zh) | 2005-06-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1217644C (zh) | 含植物提取物的美容、皮肤用组合物 | |
| JP4850397B2 (ja) | クロメン−４−オン誘導体類の使用 | |
| CN1187035C (zh) | 包含n－乙烯基咪唑聚合物或共聚物和氧化敏感亲水有效成分的组合物的化妆用途 | |
| AU2001281792B2 (en) | The use of resveratrol as sunscreen | |
| RU2454394C2 (ru) | Антиоксиданты | |
| ES2347836T3 (es) | Uso no terapeutico de un hidrolizado de proteinas de arroz como principio activo pigmentante. | |
| CN1212826C (zh) | 具有保护及再生作用的、包含艾地苯醌的局部皮肤用药 | |
| CN1205915C (zh) | 含有氨基苯酚衍生物和异黄酮类物质的化妆品组合物 | |
| JP2008538381A (ja) | 酸化防止剤 | |
| CN1993114A (zh) | 作为双核酶强效抑制剂的二芳基烷烃 | |
| CN1398580A (zh) | 含有n－酰基氨基酸酯和自我－成褐色剂的自我－成褐色组合物 | |
| WO2009157575A1 (ja) | 皮膚外用剤、美白剤、抗老化剤および抗酸化剤 | |
| JPH0616531A (ja) | 化粧料 | |
| CN1968673A (zh) | 维生素k1在化妆用配制品中作为增能剂 | |
| US20050019426A1 (en) | Use of an aqueous or hydroalcoholic extract from bauhinia for the preparation of a composition | |
| CN1173693C (zh) | 含氨基酚衍生物的化妆品组合物 | |
| CN106377451A (zh) | 一种美白霜 | |
| JPH06504282A (ja) | 化粧用又は薬用製剤 | |
| CN1359675A (zh) | 苯并二氢吡喃衍生物在美容或皮肤学制剂中的用途 | |
| CN1437580A (zh) | 3,4－二羟基苄基－取代的碳酸衍生物及其作为抗氧化剂的用途 | |
| US20030103924A1 (en) | Use of fluorescent whitening agents | |
| CN1650845A (zh) | 高脂质含量的可喷雾乳液 | |
| JPH10101543A (ja) | チロシナーゼ活性阻害剤及び化粧料 | |
| JP2001048773A (ja) | 化粧料 | |
| CN1671354A (zh) | 异黄酮在促进减肥中的应用 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C06 | Publication | ||
| PB01 | Publication | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C19 | Lapse of patent right due to non-payment of the annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |